Trial intelligence / Profile preview

Dasatinib in imatinib-resistant or -intolerant adult Ph+ ALL (China, Phase III)

CTR20160921Phase 3Terminated

Sponsor

Chia Tai-Tianqing Pharmaceutical Group

Start

Jan 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1